AF
RLMD icon

Allworth Financial’s Relmada Therapeutics RLMD Stock Holding History

Allworth Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9K Hold
2,000
– – ﹤0.01% 3257
2025
Q4 		$9.66K Buy
+2,000
New +$6.7K ﹤0.01% 3295
2023
Q4 		– Sell
-89
Closed -$267 – 3592
2023
Q3 		$267 Sell
89
-69
-44% -$205 ﹤0.01% 3191
2023
Q2 		$389 Hold
158
– – ﹤0.01% 2945
2023
Q1 		$358 Buy
158
+69
+78% +$238 ﹤0.01% 2904
2022
Q4 		$311 Buy
+89
New +$782 ﹤0.01% 2727

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Allworth Financial's RLMD Position: Q1 2026 in Review

Allworth Financial held its Relmada Therapeutics (RLMD) position steady in Q1 2026 at 2,000 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3257.

Allworth Financial first reported a position in RLMD in Q4 2022 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Allworth Financial held 2,000 shares of Relmada Therapeutics worth $13.9K as of Q1 2026.
  • Allworth Financial left its Relmada Therapeutics share count unchanged in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #3257 holding.
  • Allworth Financial first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.